334 related articles for article (PubMed ID: 32156555)
1. Disentangling ingestive behavior-related phenotypes in Prader-Willi syndrome: Integrating information from nonclinical studies and clinical trials to better understand the pathophysiology of hyperphagia and obesity.
Wevrick R
Physiol Behav; 2020 May; 219():112864. PubMed ID: 32156555
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Testing in Translational Animal Models of Prader-Willi Syndrome: Overview and Gap Analysis.
Carias KV; Wevrick R
Mol Ther Methods Clin Dev; 2019 Jun; 13():344-358. PubMed ID: 30989085
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trials in Prader-Willi Syndrome: A Review.
Mahmoud R; Kimonis V; Butler MG
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768472
[TBL] [Abstract][Full Text] [Related]
4. Calorie seeking, but not hedonic response, contributes to hyperphagia in a mouse model for Prader-Willi syndrome.
Davies JR; Humby T; Dwyer DM; Garfield AS; Furby H; Wilkinson LS; Wells T; Isles AR
Eur J Neurosci; 2015 Aug; 42(4):2105-13. PubMed ID: 26040449
[TBL] [Abstract][Full Text] [Related]
5. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
Strong TV; Miller JL; McCandless SE; Gevers E; Yanovski JA; Matesevac L; Bohonowych J; Ballal S; Yen K; Hirano P; Cowen NM; Bhatnagar A
J Neurodev Disord; 2024 Apr; 16(1):22. PubMed ID: 38671361
[TBL] [Abstract][Full Text] [Related]
6. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment.
Goldstone AP
Trends Endocrinol Metab; 2004; 15(1):12-20. PubMed ID: 14693421
[TBL] [Abstract][Full Text] [Related]
7. Advances in genetic mechanisms of hypothalamic dysfunction in Prader-Willi syndrome.
Wang XY; Sun R; Gao YQ
Yi Chuan; 2022 Oct; 44(10):899-912. PubMed ID: 36384726
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.
Tan Q; Orsso CE; Deehan EC; Triador L; Field CJ; Tun HM; Han JC; Müller TD; Haqq AM
Obes Rev; 2020 May; 21(5):e12992. PubMed ID: 31889409
[TBL] [Abstract][Full Text] [Related]
9. Prader-Willi syndrome: Hormone therapies.
Tauber M; Diene G
Handb Clin Neurol; 2021; 181():351-367. PubMed ID: 34238470
[TBL] [Abstract][Full Text] [Related]
10. Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment.
Höybye C; Barkeling B; Espelund U; Petersson M; Thorén M
Growth Horm IGF Res; 2003 Dec; 13(6):322-7. PubMed ID: 14624765
[TBL] [Abstract][Full Text] [Related]
11. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
Höybye C
Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
[TBL] [Abstract][Full Text] [Related]
12. Hormonal, metabolic and skeletal phenotype of Schaaf-Yang syndrome: a comparison to Prader-Willi syndrome.
McCarthy JM; McCann-Crosby BM; Rech ME; Yin J; Chen CA; Ali MA; Nguyen HN; Miller JL; Schaaf CP
J Med Genet; 2018 May; 55(5):307-315. PubMed ID: 29496979
[TBL] [Abstract][Full Text] [Related]
13. In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels.
Purtell L; Sze L; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
Neuropeptides; 2011 Aug; 45(4):301-7. PubMed ID: 21722955
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylation of the dopamine transporter (DAT) gene promoter is associated with hyperphagia-related behavior in Prader-Willi syndrome: A case-control study.
Wieting J; Jahn K; Eberlein CK; Bleich S; Frieling H; Deest M
Behav Brain Res; 2023 Jul; 450():114494. PubMed ID: 37182741
[TBL] [Abstract][Full Text] [Related]
15. Animal models for Prader-Willi syndrome.
Zahova S; Isles AR
Handb Clin Neurol; 2021; 181():391-404. PubMed ID: 34238473
[TBL] [Abstract][Full Text] [Related]
16. Alteration of serum leptin and LEP/LEPR promoter methylation in Prader-Willi syndrome.
Wieting J; Jahn K; Buchholz V; Lichtinghagen R; Deest-Gaubatz S; Bleich S; Eberlein CK; Deest M; Frieling H
Psychoneuroendocrinology; 2022 Sep; 143():105857. PubMed ID: 35803048
[TBL] [Abstract][Full Text] [Related]
17. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome.
Goldstone AP; Holland AJ; Butler JV; Whittington JE
Int J Obes (Lond); 2012 Dec; 36(12):1564-70. PubMed ID: 22270375
[TBL] [Abstract][Full Text] [Related]
18. Linking oxytocin and arginine vasopressin signaling abnormalities to social behavior impairments in Prader-Willi syndrome.
Oztan O; Zyga O; Stafford DEJ; Parker KJ
Neurosci Biobehav Rev; 2022 Nov; 142():104870. PubMed ID: 36113782
[TBL] [Abstract][Full Text] [Related]
19. The Prader-Willi syndrome Profile: validation of a new measure of behavioral and emotional problems in Prader-Willi syndrome.
Dykens EM; Roof E; Hunt-Hawkins H
Orphanet J Rare Dis; 2024 Feb; 19(1):83. PubMed ID: 38395848
[TBL] [Abstract][Full Text] [Related]
20. Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome.
Kuppens RJ; Diène G; Bakker NE; Molinas C; Faye S; Nicolino M; Bernoux D; Delhanty PJ; van der Lely AJ; Allas S; Julien M; Delale T; Tauber M; Hokken-Koelega AC
Endocrine; 2015 Dec; 50(3):633-42. PubMed ID: 25989955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
